Study reports substantial loss of protection one month after complete SARS-CoV-2 BNT162b2 immunization in children - News-Medical.Net

A new study evaluated the efficacy of Pfizer’s BNT162b2 vaccine in children aged 17 years or younger after the emergence of the SARS-CoV-2 Omicron variant.

A recent study posted to the medRxiv* preprint server evaluated the efficacy of Pfizer’s BNT162b2 vaccine in children aged 17 years or younger after the emergence of the severe acute respiratory synd… [+4598 chars]

full article...